CO2021015505A2 - Tratamiento de la disfunción sistólica e insuficiencia cardíaca con fracción de eyección reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida - Google Patents
Tratamiento de la disfunción sistólica e insuficiencia cardíaca con fracción de eyección reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamidaInfo
- Publication number
- CO2021015505A2 CO2021015505A2 CONC2021/0015505A CO2021015505A CO2021015505A2 CO 2021015505 A2 CO2021015505 A2 CO 2021015505A2 CO 2021015505 A CO2021015505 A CO 2021015505A CO 2021015505 A2 CO2021015505 A2 CO 2021015505A2
- Authority
- CO
- Colombia
- Prior art keywords
- heart failure
- isoxazol
- fluoroethyl
- difluoromethyl
- pyrazol
- Prior art date
Links
- 206010071436 Systolic dysfunction Diseases 0.000 title abstract 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- NREKKBAMVWQRES-MRXNPFEDSA-N danicamtiv Chemical compound FC(C1=NN(C=C1S(=O)(=O)[C@@](C)(F)C1CCN(CC1)C(=O)NC1=NOC=C1)C)F NREKKBAMVWQRES-MRXNPFEDSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849936P | 2019-05-19 | 2019-05-19 | |
| US201962852739P | 2019-05-24 | 2019-05-24 | |
| PCT/US2020/033438 WO2020236736A1 (en) | 2019-05-19 | 2020-05-18 | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021015505A2 true CO2021015505A2 (es) | 2021-12-10 |
Family
ID=70978663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0015505A CO2021015505A2 (es) | 2019-05-19 | 2021-11-18 | Tratamiento de la disfunción sistólica e insuficiencia cardíaca con fracción de eyección reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220265629A1 (enExample) |
| EP (1) | EP3972597A1 (enExample) |
| JP (2) | JP2022535195A (enExample) |
| KR (1) | KR20220009440A (enExample) |
| CN (1) | CN114173782A (enExample) |
| AU (2) | AU2020279710A1 (enExample) |
| BR (1) | BR112021023074A2 (enExample) |
| CA (1) | CA3138080A1 (enExample) |
| CL (1) | CL2021003045A1 (enExample) |
| CO (1) | CO2021015505A2 (enExample) |
| IL (1) | IL288051A (enExample) |
| MX (2) | MX2021014109A (enExample) |
| PE (1) | PE20220426A1 (enExample) |
| SG (1) | SG11202112723PA (enExample) |
| TW (2) | TW202541801A (enExample) |
| WO (1) | WO2020236736A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020315605A1 (en) | 2019-07-16 | 2022-03-03 | MyoKardia, Inc. | Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide |
| KR102752382B1 (ko) * | 2019-09-20 | 2025-01-09 | 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 | 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도 |
| IL298885A (en) * | 2020-06-15 | 2023-02-01 | Myokardia Inc | Treatment of atrial function |
| NL2026511B1 (en) * | 2020-09-21 | 2022-05-24 | Sulfateq Bv | Compounds for treatment of heart failure |
| US20250025460A1 (en) * | 2021-12-02 | 2025-01-23 | Tenax Therapeutics, Inc. | Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure |
| CN116082326B (zh) * | 2022-12-16 | 2024-12-27 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2403533A (en) * | 2003-06-30 | 2005-01-05 | Orion Corp | Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof |
| WO2005117882A2 (en) * | 2004-04-20 | 2005-12-15 | Incyte Corporation | Hydroxamic acid derivatives as metalloprotease inhibitors |
| US8324178B2 (en) * | 2008-10-31 | 2012-12-04 | The Regents Of The University Of California | Method of treatment using alpha-1-adrenergic agonist compounds |
| JP2014088342A (ja) * | 2012-10-30 | 2014-05-15 | Kowa Company Ltd | ベンゾオキサジアゾール誘導体を有効成分とするｍｋ２阻害剤 |
| PH12021553074A1 (en) * | 2015-01-22 | 2023-03-06 | Myokardia Inc | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) |
| LT3645002T (lt) * | 2017-06-30 | 2025-02-10 | Amgen Inc. | Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais |
| WO2019006325A1 (en) * | 2017-06-30 | 2019-01-03 | Equalaire Systems, Inc. | VENT CAP OF HUB CAP |
-
2020
- 2020-05-18 CA CA3138080A patent/CA3138080A1/en active Pending
- 2020-05-18 AU AU2020279710A patent/AU2020279710A1/en not_active Abandoned
- 2020-05-18 EP EP20730898.2A patent/EP3972597A1/en active Pending
- 2020-05-18 BR BR112021023074A patent/BR112021023074A2/pt unknown
- 2020-05-18 PE PE2021001920A patent/PE20220426A1/es unknown
- 2020-05-18 JP JP2021568909A patent/JP2022535195A/ja not_active Withdrawn
- 2020-05-18 KR KR1020217041155A patent/KR20220009440A/ko active Pending
- 2020-05-18 CN CN202080052078.1A patent/CN114173782A/zh active Pending
- 2020-05-18 WO PCT/US2020/033438 patent/WO2020236736A1/en not_active Ceased
- 2020-05-18 SG SG11202112723PA patent/SG11202112723PA/en unknown
- 2020-05-18 MX MX2021014109A patent/MX2021014109A/es unknown
- 2020-05-18 US US17/612,468 patent/US20220265629A1/en not_active Abandoned
- 2020-05-19 TW TW114102703A patent/TW202541801A/zh unknown
- 2020-05-19 TW TW109116586A patent/TWI874399B/zh active
-
2021
- 2021-11-11 IL IL288051A patent/IL288051A/en unknown
- 2021-11-17 MX MX2025003918A patent/MX2025003918A/es unknown
- 2021-11-18 CO CONC2021/0015505A patent/CO2021015505A2/es unknown
- 2021-11-18 CL CL2021003045A patent/CL2021003045A1/es unknown
-
2024
- 2024-12-26 US US19/001,910 patent/US20250241903A1/en active Pending
-
2025
- 2025-04-09 JP JP2025064503A patent/JP2025106475A/ja active Pending
- 2025-11-04 AU AU2025263744A patent/AU2025263744A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021003045A1 (es) | 2022-07-08 |
| US20220265629A1 (en) | 2022-08-25 |
| MX2021014109A (es) | 2021-12-10 |
| WO2020236736A1 (en) | 2020-11-26 |
| TW202110449A (zh) | 2021-03-16 |
| CA3138080A1 (en) | 2020-11-26 |
| MX2025003918A (es) | 2025-05-02 |
| BR112021023074A2 (pt) | 2022-03-29 |
| EP3972597A1 (en) | 2022-03-30 |
| SG11202112723PA (en) | 2021-12-30 |
| AU2025263744A1 (en) | 2025-11-20 |
| IL288051A (en) | 2022-01-01 |
| PE20220426A1 (es) | 2022-03-29 |
| TW202541801A (zh) | 2025-11-01 |
| AU2020279710A1 (en) | 2021-12-23 |
| JP2025106475A (ja) | 2025-07-15 |
| US20250241903A1 (en) | 2025-07-31 |
| CN114173782A (zh) | 2022-03-11 |
| KR20220009440A (ko) | 2022-01-24 |
| TWI874399B (zh) | 2025-03-01 |
| JP2022535195A (ja) | 2022-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025003918A (es) | Tratamiento de la disfuncion sistolica | |
| UY38160A (es) | Partículas implantables y métodos relacionados | |
| PE20180508A1 (es) | Amidas heterociclicas como inhibidores de quinasa | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| MX2021001957A (es) | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). | |
| ZA202204284B (en) | Inhibitors of raf kinases | |
| PH12019502048A1 (en) | Pyrimidinium compounds and their mixtures for combating animal pests | |
| PH12018501414A1 (en) | Composition and methods for cryopreservation of hutc | |
| MX2015017865A (es) | Compuestos de pirimidinodiona contra estados cardiacos. | |
| MY199353A (en) | Methods of treatment using a jak inhibitor compound | |
| NI201200016A (es) | Derivados de piridina y pirazina como moduladores de cinasa de proteína | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| CU20160111A7 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| CL2019003078A1 (es) | Nuevos derivados de pirazol bicíclicos. | |
| PE20200924A1 (es) | Compuestos de bisamida sustituida que activan el sarcomero cardiaco | |
| PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| MX2020011401A (es) | Tratamiento de combinacion para la fibrosis ocular y/o angiogenesis. | |
| MX2022008018A (es) | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina. | |
| MX2022015488A (es) | Tratamiento para la disfuncion auricular. | |
| EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
| CL2020001406A1 (es) | Combinaciones herbicidas. | |
| MX2019002615A (es) | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. | |
| CO2022000117A2 (es) | Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida | |
| LT3886799T (lt) | Kompozicija, skirta plaukų slinkimo gydymui |